Cost effectiveness analysis of larval therapy for leg ulcers by Soares, Marta O et al.
RESEARCH
Cost effectiveness analysis of larval therapy for leg ulcers
Marta O Soares, research fellow,
1 Cynthia P Iglesias, senior research fellow,
1 J Martin Bland, professor of
health statistics,
1 Nicky Cullum, professor, deputy head of department,
1 Jo C Dumville, research fellow,
1
E Andrea Nelson, reader in wound healing and director of research,
2 David J Torgerson, professor, director
York trials unit,
1 Gill Worthy, trial statistician
1 on behalf of the VenUS II team
ABSTRACT
Objective To assess the cost effectiveness of larval
therapy compared with hydrogel in the management of
leg ulcers.
DesignCosteffectivenessandcostutilityanalysescarried
outalongsideapragmaticmulticentre,randomised,open
trial with equal randomisation.
Population Intention to treat population comprising 267
patientswithavenousormixedvenousandarterialulcers
with at least 25% coverage of slough or necrotic tissue.
Interventions Patients were randomly allocated to
debridement with bagged larvae, loose larvae, or
hydrogel.
Main outcome measure The time horizon was 12 months
and costs were estimated from the UK National Health
Service perspective. Cost effectiveness outcomes are
expressedintermsofincrementalcostsperulcer-freeday
(cost effectiveness analysis) and incremental costs per
quality adjusted life years (cost utility analysis).
Results The larvae arms were pooled for the main
analysis. Treatment with larval therapy cost, on average,
£96.70 (€109.61; $140.57) more per participant per year
(95% confidence interval −£491.9 to £685.8) than
treatment with hydrogel. Participants treated with larval
therapyhealed,onaverage,2.42daysbeforethoseinthe
hydrogel arm (95% confidence interval −0.95 to 31.
91days)andhadaslightlybetterhealthrelatedqualityof
life, as the annual difference in QALYs was 0.011 (95%
confidence interval −0.067 to 0.071). However, none of
these differences was statistically significant. The
incremental cost effectiveness ratio for the base case
analysis was estimated at £8826 per QALY gained and
£40 per ulcer-free day. Considerable uncertainty
surrounds the outcome estimates.
Conclusions Debridement of sloughy or necrotic leg
ulcers with larval therapy is likely to produce similar
health benefits and have similar costs to treatment with
hydrogel.
Trial registration Current Controlled Trials
ISRCTN55114812 and National Research Register
N0484123692.
INTRODUCTION
Venous leg ulcers are a highly prevalent and costly
chronic condition in the United Kingdom.
1 In 2004
the Healthcare Commission estimated the annual
costs of treatment for leg ulcers at £300m (€340m;
$436m) to £600m. Nursing time required to manage
and treat leg ulcers is the main cost driver in the UK,
where patients with leg ulcers often make up a large
proportion of community nursing caseloads.
2 Despite
the effectiveness of high compression bandaging for
the treatment of venous leg ulcers being well
established,
3-5 not all patients are suitable or willing to
wearcompression.Furthermore,thehealingprocessis
slowandsomeulcersneverheal—thustherelevanceof
investigating the potential value of alternative treat-
ments aimed at expediting or enhancing the healing
process.
Acommonbeliefamonghealthcareprovidersisthat
the presence of necrotic tissue and slough might inter-
fere with wound healing; however, there is no strong
evidence to support this theory.
6-8 In consultation with
UK tissue viability nurses we identified that in the UK
National Health Service, hydrogel (autolytic techni-
que) can be considered the “standard therapy” for the
removalofnecrotictissue.Biologicalmethodsfordeb-
ridement, such as larval therapy, have been proposed
as a potentially effective and cost effective method for
removing necrotic tissue and are thought to promote
healing. Larvae are available in two formulations:
bagged and loose. Compared with hydrogel, each
applicationoflarvaeisexpensive(£58forlooselarvae,
£98.79forbaggedlarvae,£1.55forhydrogel)andmore
nurse consultations are likely to be required for the
application and removal of larvae up to debridement.
Although larval therapy might clean wounds more
quickly than hydrogel it is unclear whether this would
result in faster healing and reduced consumption of
healthcare resources.
Thevalueformoneyoflarvaltherapyhadbeenpre-
viouslyinvestigatedonlyinapartialeconomicanalysis
done alongside a randomised controlled trial with
12 patients. Limitations associated with the design of
this clinical study as well as the methodology used to
explore cost effectiveness compromise the confidence
wecanhaveinthepreviousconclusionthatlarvalther-
apy economically dominates hydrogel as a treatment
forlegulcers.
9Giventhisuncertaintywecarriedoutan
economic evaluation alongside a large multicentre
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effectivenessoflarvaltherapycomparedwithhydrogel
in patients with venous or mixed venous and arterial
leg ulcers. The clinical results of the trial are published
in an accompanying paper.
10
METHODS
Full details of the trial are available elsewhere.
10
Briefly, patients with venous or mixed venous and
arterial leg ulcers were eligible for recruitment if one
of the ulcers had at least 25% surface coverage with
slough or necrotic tissue. The 25% cut-off point was
adopted on the advice of tissue viability nurses, who
indicated that in practice larvae would be considered
a suitable treatment only in these circumstances.
Interventions
Participants were randomised to one of three arms:
hydrogel, loose larvae, or bagged larvae. Larvae were
left on the ulcer for three or four days, during which
time the patients received nursing care for wound
assessment and rehydration. On removal of the larvae
the treating nurse assessed the amount of slough or
necrotic tissue remaining and decided whether a
furtherapplicationwasrequired.Werefertotheappli-
cationofthedebridingagentsuntilfulldebridementor
the discontinuation of debridement treatment as the
debridement phase. Participants did not receive com-
pression while undergoing larval therapy, as this
potentiallysuffocatesthelarvae.Thistrialdesignthere-
fore relates to the pragmatic question of whether the
benefits of larval therapy outweigh the disbenefits of
going without compression during larval therapy.
Economic analysis
We carried out a cost effectiveness and a cost utility
analysis using patient level data collected within a ran-
domised controlled trial(the legulcer trial,VenUS II).
Intentiontotreatanalysescomparedincrementalcosts
with incremental ulcer-free days (cost effectiveness
analysis) and incremental quality adjusted life years
(cost utility analysis). The cost effectiveness analysis
was done using time to healing as the outcome mea-
sure. Healing was selected as the primary end point
since clinicians are motivated to debride wounds
because they believe that clean, debrided wounds
heal more quickly than non-debrided ones, and yet
there is no evidence that this is the case.
VenUSIIwasfundedbytheUKNHSandtherefore
its main objective is to inform decision making in the
NHS. In this respect the perspective for the economic
evaluations was that of the NHS and Personal Social
Services.
11Theyearofpricingwas2006.Thetimehor-
izon for the analyses was 12 months after recruitment,
and consequently we discounted neither costs nor
health benefits. The analyses were done using Stata
10 (StataCorp 2007, TX, USA).
The clinical analysis plan indicated that should evi-
dence of a statistically non-significant difference in
debridement time between loose and bagged larvae
be found, data from both larval groups would be ana-
lysed as a single group—that is, the data from both
groups would be pooled. In line with this, the incre-
mentaleconomicanalysisconsideredonlytwoalterna-
tive groups: larvae and hydrogel.
Resource use and unit costs
Wecollecteddataonuseofresourcesfromnursecom-
pletedandparticipantcompletedquestionnaires.Ana-
lysis was carried out using 2006 costs in pounds
sterling. For the purposes of costing resource use, the
following data were collected:
Debriding agents—Information about the number of
potsandunitsoflooseandbaggedlarvae,respectively,
was collected by the treating nurse at each consulta-
tion. Similarly, the number of individual hydrogel
applications was recorded at each consultation. Unit
costs for all debriding agents were obtained from the
British National Formulary and larvae suppliers. One
pot of loose larvae (LarvE, Zoobiotic, Bridgend,
Wales) was costed at £58 (300 maggots) and a half pot
at £35 (150 maggots, no longer available) plus £16.50
postagecostsineachcase.Baggedlarvae(Biobag;Bio-
monde, Barsbüttel, Germany) sachets containing 50,
100,200,and300maggotswerecostedat,respectively,
£59.26, £67.17, £79.03, and £98.79 plus £20.89 car-
riage costs for each application. Hydrogel (Purilon
Gel; Coloplast, Denmark) was costed at £1.55 per
application.
12
Healthcare consultations—Data on contacts with
nurses and doctors at home, clinics, and hospital were
available from both nurse and participant reports.
Nurse reported data were systematically collected for
only the reference ulcer, whereas participant self
reported data were collected for all ulcers and ulcer
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participants would continue recording healthcare
resource use irrespective of the healing status of the
reference ulcer. Participants’ data were therefore used
in the base case analysis. A distinction was made
between the duration of consultations at home and in
clinics (table 1). Hospital consultations were costed on
an outpatient basis.
Compression therapy—The nature of the compression
therapy applied by nurses throughout the trial was
recorded at each visit and the costs estimated as the
arithmetical average cost for commercially available
systems.
10
Table 1 provides detailed descriptions of the cate-
gories of cost and units of measurement. Other dres-
singsandtreatmentswereassumedtobeusedsimilarly
across treatmentarms and are thus not relevant for the
incremental analysis.
14
Health outcomes
Health benefit was measured in terms of ulcer-free
days and quality adjusted life years (QALYs). Time to
healing of the reference ulcer was recorded by nurses
and independently ascertained by blinded investiga-
torsusingdigitalphotographs.
10Health relatedquality
oflifedata,astheEQ-5D
15healthstatedescriptor,were
collected at baseline and at three, six, nine, and
12 months. Utility scores were calculated using an
independentpredefinedalgorithmobtainedbythe eli-
citation of societal preferences for the health dimen-
sions in a random population sample through a time
trade-off technique.
16 Thus time lived in perfect health
has a weight of 1, which decreases as health becomes
impaired.QuarterlyQALYswerecalculatedbyapply-
inganindividual’sutilityweightstosurvivaltimeusing
the area under the curve approach,
1718 which was
definedbylinearlyinterpolatingtheutilityscoresmea-
sured over time.
Statistical analysis
Estimates of expected cost and health benefit were
reported for larval therapy (pooling data from the
loose and bagged larvae groups) and hydrogel. None
the less, for completeness we present descriptive mea-
sures of costs and health benefits for each of the three
trial arms.
We used inverse probability weighting
19-21 to esti-
mate the mean time to healing, costs, and QALYs,
accounting for the censored nature of these data.
22
The weights were evaluated as the inverse of the
Kaplan Meier estimator of censoring probability. For
QALYs and cost estimation, we partitioned the study
time horizon in homogeneous subintervals (quarterly
intervals) through the weighted regression mean cost,
and QALYs were estimated within each interval and
then summed across intervals to estimate mean total
costs and QALYs.
Linearregressionwasusedtoadjusttheestimatesfor
relevant covariates: type of ulcer, duration of ulcer
(logarithmic), ulcer area (logarithmic), and centre
(aggregating centres with fewer than 10 participants),
in conformity with the clinical analysis. This accounts
for possible baseline imbalances and ensures that ran-
domisation stratification variables are appropriately
considered in the analysis. We included baseline EQ-
5D scores as a covariate in the estimation of QALYs.
17
Wecalculated95%confidenceintervalsfordifferen-
tial costs and effectiveness using non-parametric boot-
strap estimates (bias corrected).
23 For each bootstrap
resample we obtained adjusted estimates of expected
total costs and effectiveness measures.
Atreatmentstrategycanbeconsideredcosteffective
only if the decision maker’s willingness to pay for an
additional unit of health benefit is equal to or greater
than the incremental cost effectiveness ratio. The deci-
sion maker is responsible for establishing the willing-
ness to pay. Nevertheless, the treatment decision is
uncertain because expected costs and effectiveness
areestimatedunderconditionsofuncertainty.Asdeci-
sion makers have to decide on the provision of ser-
vices, we explored this uncertainty using cost
effectiveness planes and acceptability curves.
24 Given
the trial data, the acceptability curve for larval therapy
Table 1 |Unit costs (£) related to consultation with healthcare providers and hospital stay in
patients with leg ulcer
Variables Value Source
Base case analysis: patient reported data
Nurse consultations:
Duration of clinic visits (minutes) 22 VenUS I
5
Duration of home visits (minutes) 40 VenUS I
5
Cost per minute depending on location:
Clinic visits 0.667 PSSRU
13
Home visits 1.085 PSSRU
13
Travelling fixed cost for home visits 1.3 PSSRU
13
Doctor consultations:
Cost per doctor visit:
Surgery consultation 25 PSSRU
13
Home visits (including travel time) 69 PSSRU
13
Cost per ulcer related hospital stay (outpatient visit) 113 PSSRU
13
Sensitivity analysis: nurse reported data*
Duration of clinic visits, according to task:
Loose larvae application (minutes) 37 Survey
Bagged larvae application (minutes) 22.5 Survey
Dressing application (minutes) 22 VenUS I
5
Duration of home visits, according to task:
Loose larvae application (minutes) 67.3 Survey, VenUS I
5
Bagged larvae application (minutes) 40.9 Survey, VenUS I
5
Dressing application (minutes) 40 Survey, VenUS I
5
Cost per minute depending on location:
Clinic visits 0.667 PSSRU
13
Home visits 1.085 PSSRU
13
Travelling fixed cost for home visits 1.3 PSSRU
13
Visits to general practice 0.467 PSSRU
13
Hospital visits 0.667 PSSRU
13
£1.00 (€1.13; $1.45). PSSRU=Personal Social Services Research Unit.
*Costing of nurse consultations for required distinct unit costs owing to differences in data collection
instruments between patient reported and nurse reported data. Doctor and hospital unit costs were considered
as detailed for base case analysis.
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effective compared with hydrogel for a range of will-
ingness to pay values for an ulcer-free day or QALY.
This represents a Bayesian interpretation of uncer-
tainty,althoughafullBayesiananalysiswasnotunder-
taken.
Sensitivity analysis
Total costs of treating venous leg ulcers are driven by
communitynursingcostsandcostsofhospitalstay.
5As
information on contact with community nurses and
hospital visits was also collected by nurses (as well as
from participants), we explored the use of this alterna-
tive information source in sensitivity analysis. Nurses
collected data that allowed their consultations to be
costed according to the venue in which these took
place: home, clinic, general practice, or hospital. We
defined the duration of consultations by the expected
duration of treatment application (see table 1). Nurse
derived data also distinguished outpatient from inpati-
ent hospital visits; consequently costs of ulcer related
hospital stays were based on the duration of hospital
stay through a bed day cost. Nevertheless, if a partici-
pant was admitted to hospital for a non-ulcer related
reason and received ulcer treatment while in hospital,
we calculated this ulcer related cost considering only
the hospital nurses’ time. In the sensitivity analysis,
unit costs for doctor consultations and hospital stay
were the same as in the base case analysis (table 1).
Wealsoconsideredanexploratorysensitivityanaly-
sis investigating the effect of amputations. As data on
amputations were not collected systematically in the
clinical trial, the results from this analysis should be
interpreted with caution. The full trial report gives a
description of the results from this analysis.
25
RESULTS
Atotalof267peoplewererecruitedintoVenUSII:94
wereallocatedtolooselarvae,86tobaggedlarvae,and
87tohydrogel.Randomisedtreatmentswere adminis-
tered to 88 (94%), 82 (95%), and 78 (90%) participants,
respectively. Mean follow-up time was 171 days
(167 days for the loose larvae group, 170 days for the
bagged larvae group, and 175 days for the hydrogel
group).
Resource use
Debriding agents
Table2describesthenumberanddurationoftrialdeb-
ridement treatments. Participants allocated to larval
therapy received their first treatment application
about three days later than participants allocated to
hydrogel, owing to the need to order the larvae. Parti-
cipants in either larval therapy arm received on aver-
age 1.45 applications before the debridement
treatment was discontinued or data were censored
compared with on average 9.2 applications in the
hydrogel arm.
Table 2 |Characterisation of trial debridement treatment and patient reported resource use*.
Values are numbers (percentages) unless stated otherwise
Variables Loose larvae (n=94) Bagged larvae (n=86) Hydrogel (n=87)
Time until first treatment
application (days)
Mean (SD) 5.09 (3.86) 5.61 (4.46) 2.49 (3.99)
Missing 7 (7) 7 (8) 8 (9)
Noofapplicationsoftrialtreatment:
Mean (SD) 1.44 (1.22) 1.46 (1.06) 9.2 (27.78)
Missing 5 (5) 4 (5) 5 (6)
Duration of trial treatment (days):
Mean (SD) 11.95 (9.11) 12.84 (11.47) 43.17 (51.76)
Missing 6 (6) 4 (5) 9 (10)
Nurse consultations related to
ulcers:
Mean (SD) 37 (40) 36 (41) 39 (45)
Missing 6 (6) 4 (5) 5 (6)
Doctor consultations related to
ulcers:
M e a n( S D ) 2( 4 ) 3( 5 ) 4( 9 )
Missing 6 (6) 4 (5) 5 (6)
Hospital visits related to ulcers:
Mean (SD) 10 (20) 7 (15) 5 (12)
Missing 6 (6) 4 (5) 5 (6)
Highest compression level used:
N o n e 7( 7 . 5 ) 4( 4 . 7 ) 1( 1 . 2 )
Low 18 (19.2) 22 (25.6) 20 (23.0)
High 64 (68.1) 56 (65.1) 61 (70.1)
Missing 5 (5.3) 4 (4.7) 5 (5.8)
*Healthcare resource use by treatment arm is further detailed in Dumville et al.
10
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treatment:dataonnursevisitsweremissingfor14par-
ticipants, whereas five received a treatment other than
thetrialtreatment(oneinthelooselarvaearmandfour
in the hydrogel arm). The duration of trial treatment
was, on average, 30 days longer in the hydrogel arm
than in the larval therapy arms (43 v 12 days).
Healthcare consultations
Table 2 details the number of patient reported health-
care consultations related to ulcers. The average num-
bers of total consultations with healthcare
professionals in the follow-up period were similar
acrossgroups(59forlooselarvae,56forbaggedlarvae,
and 61 for hydrogel), with most visits being ulcer
related (81% overall, 47/58). Nurse consultations
accounted for 71% of the total number of healthcare
consultations (42/59).
Compression therapy
The use of high and low compression bandaging (at
least once in the trial) was similar across the three
arms (table 2): compression was received by 87% of
participants (82/94) in the loose larvae arm, 91%
(78/86) in the bagged larvae arm, and 93% (81/87) in
the hydrogel arm.
Total costs
The average estimated cost of the trial treatment per
applicationwas:loose larvae£71.70(SD £13.40; mini-
mum-maximum: £51.50-£132.50), bagged larvae
£111.90 (SD 33.6; £80.10-£218.50), and hydrogel
£1.50 (SD 0).
The mean total unadjustedcosts incurred by partici-
pants allocated to each of the trial arms was £1833 (SD
£1978) for the loose larvae arm, £1696 (SD £1948) for
the bagged larvae arm, and £1596 (SD £1861) for the
hydrogelarm.Thecostofnurseandhospitalvisitswas
the major driver of total costs, representing 85% for
loose larvae, 77% for bagged larvae, and 82% of the
totalunadjustedcostsofpatientsallocatedtohydrogel.
Half of the mean incurred costs observed during the
trial (available case analysis) were incurred during the
first three months of follow-up in all treatment arms.
The analysis adjusted for censoring, baseline imbal-
ances,and stratificationvariablesshowsthattreatment
with larvae costs, on average, £96.70 more per partici-
pant per year (95% confidence interval −£491.90 to
£685.80) than treatment with hydrogel (table 3). This
difference was not statistically significant.
Health outcomes
On average and after adjustment for baseline imbal-
ances and stratification variables, participants treated
withlarvaltherapyhealed2.42daysbeforethoseinthe
hydrogel arm. However, this difference was not
Table 3 |Adjusted base case analysis*: annual costs (£), time to healing, and quality adjusted
life years (QALYs)
Variables
Mean (95% CI)
annual costs
Mean (95% CI) time to
healing (days)
QALYs
(95% CI)
Hydrogel 1976.4 (1521.4 to 2500.2) 206.5 (202.7 to 260.2) 0.540 (0.489 to 0.589)
Larval therapy 2073.1 (1724.4 to 2433.4) 204.1 (207.9 to 248.3) 0.551 (0.505 to 0.591)
Difference† 96.7 (−491.9 to 685.8) −2.42 (−41.0 to 31.9) 0.011 (−0.067 to 0.071)
£1.00 (€1.13; $1.45).
*Adjusted for type of ulcer, duration of ulcer (logarithmic), ulcer area (logarithmic), centre (aggregating centres
with fewer than 10 elements). Additional adjustment for baseline utility in estimation of QALYs.
†Larval therapy compared with hydrogel.
Table 4 |Unadjusted utility weights (EQ-5D) by arm and time. Values are numbers (percentages) unless stated otherwise
Follow-up Loose larvae (n=94) Bagged larvae (n=86) Hydrogel (n=87)
Baseline:
Mean (SD) 0.534 (0.301) 0.434 (0.342) 0.539 (0.313)
Median 0.648 (−0.239 to 1) 0.587 (−0.349 to 1) 0.62 (−0.239 to 1)
Missing 8 (9) 5 (6) 6 (7)
3 months:
Mean (SD) 0.551 (0.343) 0.562 (0.33) 0.559 (0.317)
Median 0.620 (−0.594 to 1) 0.620 (−0.349 to 1) 0.620 (−0.181 to 1)
Missing 23 (24) 18 (21) 16 (18)
6 months:
Mean (SD) 0.596 (0.334) 0.588 (0.339) 0.566 (0.301)
Median 0.691 (−0.594 to 1) 0.587 (−0.349 to 1) 0.689 (−0.181 to 1)
Missing 33 (35) 25 (29) 26 (30)
9 months:
Mean (SD) 0.608 (0.345) 0.561 (0.381) 0.628 (0.315)
Median 0.691 (−0.594 to 1) 0.620 (−0.239 to 1) 0.691 (−0.349 to 1)
Missing 41 (44) 33 (38) 38 (44)
12 months:
Mean (SD) 0.630 (0.329) 0.565 (0.382) 0.615 (0.322)
Median 0.691 (−0.594 to 1) 0.620 (−0.181 to 1) 0.674 (−0.239 to 1)
Missing 47 (50) 41 (48) 43 (49)
RESEARCH
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−40.95 days to 31.91 days; see table 3).
Table 4 presents the quarterly utility scores per par-
ticipant by trial arm. The adjusted results show that
patients in the larval therapy arms had, on average, a
slightly better quality of life than those in the hydrogel
arm (annual difference in QALYs 0.011, 95% confi-
dence interval −0.067 to 0.071; see table 3).
Cost effectiveness and associated uncertainty
The incremental cost effectiveness ratio associated
with use of larval therapy was estimated at £8826 per
QALY gained and £40 per ulcer-free day. The point
estimates of cost and effect differences were small rela-
tive to their standard error, indicating considerable
uncertaintyassociatedwiththedecisiontoadoptlarval
therapy (see table 3).
Despite the point estimate for the incremental cost-
utility ratio (£8826) being below the £30000 per
QALYthatisgenerallyacceptedasbeinga“threshold”
of cost effectiveness by the National Institute for
Health and Clinical Excellence, considerable uncer-
tainty surrounds this estimate. This uncertainty can
be displayed in two ways. In the cost effectiveness
plane (fig 1), 4000 bootstrapped incremental costs
and utilities are scattered to represent the joint uncer-
tainty distribution. A similar density is seen across all
quadrantsoftheplane,meaningthatthe probability of
larvae being eithercost saving and more effective than
hydrogel or more costly and less effective are similar.
The cost effectiveness acceptability curve (fig 2),
plotted for a range of willingness to pay thresholds
(costperQALY),suggeststhatinthebasecaseanalysis
theprobabilityoflarvaebeingcosteffectiveinrelation
to hydrogel never exceeds 63%.
Sensitivity analysis
A sensitivity analysis was done to assess the impact on
the costeffectivenessestimatesofusingnursereported
dataonconsultationsratherthanpatientreporteddata,
as in the base case analysis. The number of consulta-
tions and hospital stays (nurse reported) was slightly
lower thanthat reportedby patients,butsimilar across
the three arms (38 nurse visits per patient in each arm
andatotalnumberofsevenulcerrelatedhospitalstays
in patients allocated to loose larvae, four allocated to
bagged larvae, and two allocated to hydrogel). This
may be because nurses did not continue to collect
data on resource use after the reference ulcer had
healed. The use of nurse reported data allowed us to
distinguish between hospital consultations and inpati-
ent stays and to cost them appropriately.
After adjustment for baseline imbalances and strati-
fication variables, cost estimates from the sensitivity
analysis indicated lower costs were incurred by larvae
users. On average participants in the larvae group cost
£31.30lessthanthoseinthehydrogelgroup;however,
this difference was not statistically significant (table 5).
As only costs are subjected to sensitivity analysis, the
cost effectiveness or utility was based on the health
benefits estimates of the base case analysis. The deci-
sion to adopt larval therapy was still associated with
considerable uncertainty (fig 3).
DISCUSSION
Our base case analysis indicates that, compared with
hydrogel, larval therapy confers a small health benefit
forpeoplewithlegulcers,asmeasuredbyQALYsand
time to healing, at a minor additional cost to the
UK NHS. The incremental cost effectiveness ratio for
the base case analysis was estimated at £8826 per
QALY gained and £40 per ulcer-free day. Yet our
non-parametric confidence intervals indicated a high
level of uncertainty associated with the differential
cost,effectiveness,andcosteffectivenessoflarvalther-
apy compared with hydrogel. The spread of points on
the cost effectiveness plane was almost uniform over
the four quadrants, suggesting that the nature of the
uncertainty associated with our results is such that lar-
val therapy is likely to be as costly and as effective as
hydrogel.
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Fig 3 | Sensitivity analysis cost effectiveness acceptability
curve
Table 5 |Adjusted sensitivity analysis*
Arm Scenario: annual costs (£) (95% CI)
Hydrogel 2369.9 (1773.6 to 3004.7)
Larval therapy 2338.7 (1964.5 to 2719.1)
Difference† −31.3 (−726.0 to 707.9)
*Adjusted for type of ulcer, duration of ulcer (logarithmic), ulcer area
(logarithmic), centre (aggregating centres with fewer than 10 elements).
†Larval therapy compared with hydrogel.
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Sensitivity analysis showed that the uncertainty could
notberesolvedbyusingalternativedatatoestimatethe
number of contacts with healthcare providers. While
in this analysis the point estimate for cost effectiveness
suggested “dominance” of larval therapy—that is, lar-
val therapy being better and cheaper than hydrogel—
the uncertainty associated with this result was consis-
tent with the base case analysis suggesting no differ-
ence between larval therapy and hydrogel in terms of
health benefits or costs.
Debridement and health related quality of life
The impact of larval therapy on health related quality
oflife(as measuredthrough theEQ-5D and SF-12
10)i s
unclear.Asaconsequenceofthehighlevelsofmorbid-
ity in patients with leg ulcers, it could be argued that
generic health related quality of life instruments might
not capture the benefits of ulcer treatments. Previous
work, however, showed that both the SF-12 and
EQ-5D are sensitive to, and thus able to measure,
changes in healing status of patients with venous leg
ulcer.
26 That said, the influence of a clean ulcer on
health related quality of life has never been studied.
Although debridement was more rapid with larval
therapy, measurement of its effect on health related
quality of life might have been hindered by some fac-
tors.Healthrelatedqualityoflifedatawerecollectedat
quarterly intervals whereas the median time for debri-
dement in the larvae groups was between 14 and
28 days
10; this time gap might have interfered with
the instrument’s ability to capture any small changes
in health related quality of life. Interestingly, in a
qualitative study carried out as part of our randomised
controlledtrial(VenUSII),arelativelyquickreappear-
ance of necrotic tissue was reported by previous users
oflarvaltherapy,suggestingthatanypositiveeffectsin
healthrelatedqualityoflifeassociatedwithlarvalther-
apy maybe shortlived.In addition,larval therapywas
associatedwithincreasedlevelsofpain,
10andtherefore
if the time between debridement and reappearance of
slough is short then any potential benefits on health
related quality of life associated with larval therapy
may be cancelled out.
Data characteristics
Animportantcharacteristicofourdatasetwasthehigh
proportion of censored data. Heavy censoring is not
unusual in studies focusing on patients with high mor-
bidity and frequent transfers between hospital and
communityhealthcaresettings.Baselinehealthrelated
quality of life scores indicated a higher than average
levelofmorbidityamongthepopulationunderevalua-
tion, which may account for more than 40% of partici-
pants failing to complete the health related quality of
life questionnaires at the final follow-up. Inverse prob-
abilityweightingmethodswereusedtoaccountforthis
importantfeatureofourdataintheestimationofmean
health benefits and costs.
In this cost effectiveness analysis, healing was the
event of interest; individuals lost to follow-up were
censored as were those who died. As healing cannot
occur after death, censoring in such cases may conflict
with the assumption common to most methods of sur-
vivalanalysis—thatis,thatcensoringisindependentof
the outcome (non-informative censoring). The impact
of this approach to censoring could be explored using
multistate models.
27
Strengths and weaknesses of the economic analysis
This is the first full economic evaluation alongside a
randomised controlled trial evaluating the value for
money of a single phase of larval therapy (loose or
bagged) compared with hydrogel for the debridement
and healing of venous and mixed aetiology leg ulcers
over a period of 12 months. The only existing analysis
is a partial cost consequences analysis with a one
month time horizon and an intermediate outcome—
debridement—as a measure of health benefit.
9
Leg ulcers are a recurrent condition, and conse-
quently it could be argued that to ascertain fully the
expected value for money of debriding agents, an eco-
nomic analysis based on a comprehensive decision
analytic model should be done. Given the limited
knowledge about the role and value of debridement
in the healing process and the relatively rare preva-
lence of large amounts of necrotic tissue in leg ulcers
(indicated by the results of the eligibility screening for
this trial) we restricted the time horizon of this analysis
to the duration of the trial.
While our findings have strong external validity for
the UK NHS, the applicability of these results to other
settings worldwide may require further consideration.
Variations on the use of debriding agentsmay have an
impact on the cost effectiveness of these treatments.
Recommendations for future research
Inpracticeseveralothermethodsareavailablefordeb-
riding wounds, and thus when making choices about
type of debridement treatment decision makers are
faced with a more complex decision than that repre-
sented by this trial. To make an informed decision
from this wide selection of treatmentoptions to ensure
that the most cost effective treatments are used, data
fromthisrandomisedcontrolledtrialandotherstudies
should be incorporated into decision analytic models.
The potentialrelevance ofimportant adverse events
such as amputations may warrant further analysis.
25
While there is no evidence of a differential rate of
amputations between these debridement treatments,
given the substantial clinical and economic implica-
tions of this event future studies on leg ulcer should
systematically collect data on amputations to be
included in economic analyses.
Conclusions
In conclusion, one phase of larval therapy used until
initial debridement of leg ulcers is likely to produce a
similarlevelofhealthbenefitatasimilarcosttohydro-
gel.Itcouldbearguedthathealthcaredecisionmakers
should be indifferent when recommending these two
RESEARCH
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ulcersorthatthedecisionshouldbedrivenbythegoal
oftreatment(forexample,ifdebridinganulcerrapidly
is important when a skin graft is planned). The choice
of treatment may then be driven by patients’ wishes
and experiences of pain with larvae.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Larval therapy, a traditional approach to wound management, is widely used on leg ulcers
Only one randomised trial with 12 participants has been carried out previously and did not
measure ulcer healing or do a full cost effectiveness analysis
WHAT THIS STUDY ADDS
Larval therapy for the debridement of sloughy or necrotic leg ulcers is likely to have similar
cost effectiveness to hydrogel
Healthcare decision makers should generally be indifferent when recommending these two
treatments
The choice of treatment may then be driven by patients’ wishes and experiences of pain with
larvae
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